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Introduction
Human African trypanosomiasis (HAT) is caused by Trypanosoma brucei sspp.
Manifestation of 'sleeping sickness', or chronic-stage HAT, occurs when the parasites migrate into the central nervous system (CNS). Although fewer than 7000 cases are reported each year, nearly 70 million people remain at risk [1] . Current therapies are limited by toxicity, route of administration and stage-specific activities [2] . Two drugs are currently undergoing clinical trials: fexinidazole and the oxaborole SCYX-7158 [3] .
Fexinidazole, which offers a potential new safe oral treatment, was rediscovered during a screening programme against T. brucei by the Drugs for Neglected Diseases Initiative in 2005 [4] , and completed Phase II/III trials for the treatment of chronic-stage HAT in April 2015 [5, 6] , with drug registration planned by the end of 2016 [7] . Preclinical studies showed oral effectiveness in curing both chronic and acute stages of the disease in mice [8] . Fexinidazole is metabolized rapidly by a range of cytochrome P450 enzymes, including CYPs 1A2, 2B6, 2C19, 3A4 and 3A5, and flavin-containing mono-oxygenase into two active metabolites: fexinidazole sulfoxide and fexinidazole sulfone [6, 8, 9] .
The recently completed Phase II/III clinical trials performed in Africa compared the safety and efficacy of fexinidazole treatment with that of the combination therapy NECT (nifurtimox and eflornithine) [3] . The 10-d oral fexinidazole treatment regimen currently being implemented is 1800 mg/d (3 x 600 mg taken with food) for 4 d followed by 1200 mg/d for 6 d (2 x 600 mg taken with food). Clinical studies also aim to determine if lower doses and shorter treatment regimens can be used [7] .
Studies on fexinidazole in mice were undertaken to: (i) further validate the use of optical imaging [10] in a T. brucei mouse model with acute and chronic infection to monitor drug effect in real-time, and measure dose response and time-kill [11] ; (ii) determine any differences in pharmacokinetics between infected and uninfected mice; and (iii) expand pharmacokinetic studies to the CNS using microdialysis to provide data on the distribution of fexinidazole and its metabolites. This study aimed to provide further knowledge on the relationship between drug exposure, parasite distribution and rate of kill, as well as to test the full potential of the mouse imaging model.
Methods and materials

Parasites
The red-shifted bioluminescent T. b. brucei strain GVR35-VSL-2 [10] was used in all infection studies. This parasite strain produces a chronic infection in mice 21 d postinfection (D21 p.i.), as detailed in previous studies [11] .
Drug sources
Fexinidazole was kindly provided by Dr Benedict Blayney, Sanofi, France.
Fexinidazole sulfone and sulfoxide were generously donated by Dr Stephen
Patterson from Drug Discovery Unit, University of Dundee, UK.
Animal models
The experimental protocol was performed with the approval of the UK Home Office Female CD1 mice weighing 20-25 g (Charles River Laboratories, Wilmington, MA, USA) were housed in specific-pathogen-free individually vented cages, and fed ad libitum. Mice were infected with 5 x 10 3 trypanosomes/mL from a donor mouse by the intravenous route, as detailed previously [11] , and randomized into three animals per cage (two cages = one experimental group). ARRIVE guidelines were adhered to in this report [12] .
Drug dose effect in vivo
The protocol to assess the drug efficacy of fexinidazole using bioluminescence imaging (BLI) has been described previously [11, 13] and 12 h), mice were culled and plasma was collected by centrifugation of heparinized blood at 2000 g for 10 min. The plasma was then snap frozen on dry ice and stored at -80C. Brain samples were also collected after perfusion with PBS via the hepatic portal vein, before being snap frozen on dry ice and stored at -80C. Calibration standards for quantification of analyte concentrations in plasma were prepared by spiking aliquots of control plasma with specific amounts of analyte to
Sample preparation
give nominal concentrations over the ranges 1-5000 ng/mL for fexinidazole and 50-50 000 ng/mL for each of the metabolites. Calibration standards for brain were prepared by spiking control brain homogenate to give nominal concentrations over the ranges 2-10 000 ng/g for fexinidazole and 10-40 000 ng/g for each of the metabolites. Calibration standards were prepared for analysis alongside study samples using the same method.
Brain and plasma sample analysis
The brain and plasma extracts were analysed for fexinidazole and its sulfoxide and sulfone metabolites using an Agilent 1290 UHPLC and autosampler combined with an Agilent 6550 QTof iFunnel mass spectrometer (Agilent Technologies, Craven
Arms, UK). Extracts were thawed and diluted 1:1 with water, and 6-µL aliquots were injected on to an Agilent RRHD C18 column (50 mm x 2.1 mm, 1.8 µm) maintained at 50 °C in a column oven. Sample components were eluted from the column using a mobile phase consisting of aqueous formic acid (0.1% v/v, Channel A) and acetonitrile containing 0.1% v/v formic acid (Channel B); a gradient elution programme increased the proportion of B from 2% to 95% between 0.5 and 1.3 min p.i., maintained at 95% until 2.5 min, before returning to 2% at 2.6 min p.i.
The mass spectrometer was operated in positive ion electrospray mode scanning m/z 100-1000 in 0.3 s. The instrument was calibrated before data acquisition, and internal references were infused continuously to compensate for any drift during the course of the run. Peaks in extracted ion chromatograms [corresponding to the expected mass/charge ratios (accurate to four decimal places) of singly protonated analyte molecules, with windows of ± 20 ppm] were integrated and quantified against calibration curves generated using MassHunter v B.05.01 software (Agilent).
Microdialysis
Surgical procedure
General anaesthesia was induced using isofluorane (5% in O 2 ) and maintained at 2% during the surgery. Microdialysis guide cannulae (MAB8, Microbiotech, Stockholm, Sweden) were stereotaxically implanted simultaneously into the prefrontal cortex (PFC) (AP +2.1, DL −0.5, V −1.0) and the ventral hippocampus (VH) (AP −2.9, DL +2.7, V −1.7) (co-ordinates in mm from bregma/dura) [14] of female CD1 mice (n=3). Guide cannulae were secured with acrylate cement and a tether anchor screw (Instech, Plymouth Meeting, PA, USA) attached. On completion of surgery, animals were administered analgesics and subcutaneous saline, and placed in an incubator until they regained their righting reflex. Mice were used in experiments 48 h after surgery.
Microdialysis procedure
Microdialysis was performed according to methodology described previously [15] . On the day prior to the experiments, animals were placed in microdialysis cages for 
Analysis of microdialysis samples
Microdialysis samples were analysed using an Agilent 1200 high-performance liquid chromatography system combined with an Agilent 6410A triple quadrupole mass spectrometer. A mobile phase of water/0.1% formic acid (Channel A) and acetonitrile/0.1% formic acid (Channel B) was used to elute sample components from a Kinetex column packed with 5 µm of C 18 material (2.1 mm x 50 mm at 50°C).
The mobile phase composition was held at its initial 5% B for 0.1 min p.i., then programmed to increase linearly to 95% B at 1.2 min; after a further 0.5 min at 95% B, the composition was returned to its initial 5% B at 1.80 min p.i. 
Results
Drug effect
VSL-2 infected mice were treated with fexinidazole at 7.4, 22.2, 66.7 and 200 mg/kg, six mice per dose [9] . BLI and parasitaemia were assessed prior to treatment on D21 p.i. and then on D25, 28, 30 and 35 p.i. (Fig. 1) .
The BLI data showed that by D25, only the 66.7 mg/kg and 200 mg/kg doses were able to reduce the bioluminescence signal (the loss in bioluminescence can be seen Page 11 of 25 in Fig. 1A ). The bioluminescence in the 7.4 mg/kg dose group decreased after treatment (indicated as blue areas in Fig. 1A ), but was above background detection, whereas the 22.2 mg/kg dose group exhibited a reduction in bioluminescence, with just the highly vascular areas of the nose and feet having a detectable signal. Three days later on D28, mice treated with the highest doses of 66.7 and 200 mg/kg fexinidazole were still negative for detectable bioluminescence. Relapse of trypanosome infection occurred in the mice treated with 7.4 mg/kg fexinidazole on D28, with disseminated bioluminescence levels similar to D21, while the 22.2 mg/kg dose group also showed increased BLI levels.
By the end of the experiment (D35), three of the four doses had relapsed, with relative levels of bioluminescence indicating a dose-dependent effect (Fig. 1B) . The 66.7 mg/kg treatment group, despite showing no detectable bioluminescence 7 d earlier on D28 p.i. (Fig. 1A) , had early stages of drug relapse, with bioluminescence being present throughout the entire animal. Mice treated with 200 mg/kg fexinidazole showed no bioluminescence on D35, indicating that the mice were clear of infection.
In order to quantify the dose-dependent effect, the mean bioluminescence of each group was determined and shown in relation to days p.i. in On D35, the end of the experiment, both the T. b. brucei GVR35-VSL-2 and wildtype-infected mice were culled and the perfused brains were removed for quantitative PCR analysis to determine parasite burden. The excised brains of the VSL-2 mice were also imaged prior to freezing (Fig. 1C) . The BLI and quantitative PCR data (Fig. 1C) of the excised brains reflected the whole animal imaging; in other words, increasing doses of fexinidazole resulted in lower bioluminescence and a decrease in parasitic burden.
Pharmacokinetics of fexinidazole and its metabolites.
A study to investigate the pharmacokinetics of fexinidazole and its metabolites was for sulfone for uninfected and infected animals, respectively).
The total exposure of fexinidazole and its two main metabolites in plasma and brain were similar between the infected and uninfected groups (Tables 1 and 2 ). There is perhaps a suggestion of a trend for exposure in the infected group to be lower, but the relatively high variability observed for concentrations at replicate time points means that this cannot be confirmed.
Microdialysis
Recovery of fexinidazole in microdialysates was estimated using the in-vitro recovery method [16] . In the presence of 1% 2-hydroxypropyl-β-cyclodextrin, recovery of fexinidazole was 14.7% at 25 ng/mL and 13.8% at 100 ng/mL. Recoveries for the sulfoxide and sulfone metabolites were not determined, so only qualitative comparisons between concentrations of fexinidazole and its metabolites are discussed. Concentrations quoted for fexinidazole and its metabolites have all been corrected by a factor corresponding to the mean recovery for fexinidazole at the two concentrations tested. Concentrations quoted for metabolites may therefore be subject to additional error due to the potential for differences in recovery.
The microdialysis studies showed that unbound fexinidazole and its metabolites were present in the interstitial fluid (ISF) of both brain regions investigated in this study (PFC and VH). Plots of concentration against sampling time (Fig. 4) show fairly marked interindividual variability. For example, Mouse 2 showed C max for fexinidazole of ca. 60 ng/mL in both PFC and VH, with the other two replicates showing C max of <5 ng/mL. However, concentration vs time profiles within individual animals for the three compounds in ISF sampled from PFC and VH showed consistent trends.
Discussion
Previous publications [10, 17, 18] have shown how the BLI mouse model of infection for HAT can be used to identify compounds with activity against the CNS stage of infection, and significantly shorten the time of the assay. The present study shows show how the model can be used to determine: (i) the dose-response effect and rate of kill; (ii) the difference in pharmacokinetics of a drug between infected and uninfected mice; and (iii) the actual free drug concentrations in the CNS compartment using microdialysis.
The use of static pharmacokinetic/pharmacodynamic models to evaluate preclinical drug profiles has not accounted for drug-parasite interactions or how well the drug distributes through both the plasma and tissue [19] . By using a dynamic model that looks at the relationship between drug distributions within the plasma and tissue and the rate of kill of a drug (concentration and/or time dependent), an understanding of drug exposure can be established [20] . By using the bioluminescence model to detect the dose-dependent effect of fexinidazole, the time-kill properties of the drug during a real-time infection were assessed, showing that fexinidazole is dose dependent as relapse occurred early at the lower doses of 22 mg/kg and 66.7 mg/kg.
Comparing the pharmacokinetic profiles of fexinidazole and metabolites between both the infected and uninfected mice, it appears that trypanosome infection did not alter the metabolism and disposition of fexinidazole significantly.
Both fexinidazole and its sulfoxide metabolite showed two maxima in their concentration vs time profiles in both plasma and brain. The first T max was ca. 0.5-1.0 h post-dose with a secondary maximum in concentration at the 6-h time point.
This was seen in all replicates in both plasma and brain, and is perhaps a consequence of a food effect as observed by Tarral et al. [8] . high variability between animals, with C max values ranging from 9 ng/mL to 372 ng/mL for fexinidazole from the PFC. Interindividual variability was also seen in human plasma concentrations after the administration of a single dose, and was noted to be apparent with the parent and metabolites [8] .
Fexinidazole will be used to treat HAT patients with a dose regimen of 1800 mg/d for between human and mouse [21] . Other factors that have an impact, such as BBB permeation which differs between infected mice and humans [22] , parasite distribution and burden, have not been determined.
Fexinidazole has shown promising results in other kinetoplastid diseases, with its efficacy also being assessed against Chagas disease and leishmaniasis [23] .
Studies carried out on Chagas disease found that the active metabolites of sulfoxide and sulfone were more effective in curing an acute in-vivo mouse model of T. cruzi than the parent drug [23] . In visceral leishmaniasis, both fexinidazole and its metabolites were shown to be effective orally, with good distribution and absorption of the drug in the target organs of the liver and spleen [24] . These studies suggest that oral fexinidazole has potential as a new treatment for all kinetoplastid diseases. the analysis showed that there was a significant difference between the two sets of data (P=0.0012). **P ≤ 0.01. 
